Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KRAS Mutant Antigen Specific TCR-T Cells in Advanced Solid Tumors
NCT05438667Phase 1Terminated
- Sponsor
- Sun Yat-sen Memorial Hospital
- Start
- Jun 2023
- Primary completion
- Jun 2026
- Modality
- TCR-Engineered T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of KRAS mutant antigen specific TCR-T cells in solid tumor, sponsored by Sun Yat-sen Memorial Hospital. Primary endpoint: Objective Response Rate at 12 months. Started Jun 2023; status: terminated.
02
Drugs
KRAS mutant antigen specific TCR-T cells
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05438667.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05438667.